Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2001

View Archived Issues

Hollis-Eden receives approval to begin U.S. clinical trials with HE-2200

Enrollment completed in phase III clinical trial of T-20

Glycogen synthase 3 as a novel therapeutic target in type 2 diabetes

U.S. and French researchers investigate novel peptide vectors for gene, protein delivery

Potent analogues of hPTH and hPTHrP with bone anabolic effects

Gene and cell cycle effects elucidated for NB-1011

Orphan Medical receives approvable letter for Xyrem from FDA

Microbiological efficacy and safety of oritavancin in Gram-positive bacteremia

Nippon Shinyaku to market and distribute DepoCyt in Japan

Nexell submits IND for blood stem cell therapy as treatment of CGD

Aspirin-like compound exerts promising anti-HIV activity via a novel mechanism of action

Insulin sensitization with rosiglitazone may have numerous beneficial effects

Cyberonics launches VNS therapy for depression in Europe

Company begins phase I evaluation of XTL-002 for treatment of HCV

Schering-Plough seeks FDA approval for new formulation of PEG-Intron

Preliminary clinical results reported for Durect's Chronogesic

Old drug for diabetic neuropathy may be useful in migraine prophylaxis

PowderJect acquires SBL Vaccin

New LTB4 antagonists designed at Lilly for inflammation

Inhibitors of phosphodiesterase, TNF-alpha production and their use described by Merck

Cytovia presents new series of caspase activators and apoptosis inducers

Ortho-McNeil describes novel inflammatory cytokine inhibitors

Thrombopoietin mimetics in development at GSK

New NAALADase inhibitors from Guilford protect against cerebral ischemic insult

Neurogen's benzodiazepine-site ligands particularly useful for Rx of CNS disorders

Celgene team patents inhibitors of PDE4, TNF-alpha production and NF-kB activation

Xanthine-based adenosine receptor antagonists with particular utility in heart and renal failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...